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Abstract: Background: Extracts of several members of the monoterpene-rich Lamiaceae sub-family
Nepetoideae, including those from the Salvia (sage), Melissa (Lemon balm) and Rosmarinus (rosemary)
genera, evince cognitive and mood effects in humans that are potentially related to their effects
on cholinergic and GABAergic neurotransmission. To date, despite promising in vitro properties,
the cognitive and mood effects of the closely related Mentha spicata (spearmint) and Mentha piperita
(peppermint) remain unexplored. This study therefore assessed the human cognitive/mood
effects of the M. spicata/piperita essential oil with the most promising, brain-relevant in vitro
properties according to pre-trial in vitro screening. Design: Organic spearmint and peppermint
(Mentha spicata/piperita) essential oils were pre-screened for neurotransmitter receptor binding and
acetylcholinesterase (AChE) inhibition. In a double-blind, placebo-controlled, balanced cross-over
study, 24 participants (mean age 25.2 years) consumed single doses of encapsulated placebo and
50 µL and 100 µL of the most promising essential oil (peppermint with nicotinic/GABAA receptor
binding and AChE inhibitory properties, that increased calcium influx in a CAD cell neuronal model).
Psychological functioning was assessed with mood scales and a range of standardised, cognitively
demanding tasks pre-dose and at 1, 3 and 6 h post-dose. Results: The highest (100 µL) dose of essential
oil improved performance on the cognitively demanding Rapid Visual Information Processing task
(RVIP) at 1 h and 3 h post-dose and both doses attenuated fatigue and improved performance of
the Serial 3 s subtraction task at 3 h post-dose. Conclusion: Peppermint (Mentha piperita) essential
oil with high levels of menthol/menthone and characteristic in vitro cholinergic inhibitory, calcium
regulatory and GABAA/nicotinic receptor binding properties, beneficially modulated performance
on demanding cognitive tasks and attenuated the increase in mental fatigue associated with extended
cognitive task performance in healthy adults. Future investigations should consider investigating
higher doses.
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1. Introduction
The Lamiaceae, or mint family of flowering plants, comprises over 7000 plant species. Its largest
sub-family, the Nepetoideae, comprises numerous species, including those in the genera Origanum
(oregano), Ocimum (basil), Thymus (thyme), Salvia (sage), Lavandula (lavender), Melissa (Lemon balm),
Rosmarinus (rosemary) and Mentha (mint; e.g., spearmint (M. spicata L.) and peppermint (M. piperita L.)).
Plants in these genera typically synthesize high concentrations of volatile and pleasantly odorous
mono-/sesqui-terpenes which include menthol, menthone, menthofuran, isomenthone, (E)-caryophyllene,
1,8-cineole, linalool, limonene, carvone, pulegone and α-terpineol [1]. Consequently, this plant group
is a particularly rich source of essential oils (usually a steam-distilled liquid containing volatile aroma
compounds). Evidence suggests that the psychotropic properties of the above plants reside in these volatile
constituents and, as a consequence, the essential oils they produce may also exert neurocognitive effects.
As an example, in vitro studies show that Lemon balm (Melissa officinalis L.) essential oil
has an affinity for gamma-aminobutyric acid A (GABAA) receptors and exert a net depressant
effect on neuronal activity (commensurate with anxiolytic effects) as assessed by patch clamp
electrophysiology [2]. Several randomised, double-blind, placebo-controlled, balanced-crossover trials
have also demonstrated anxiolytic-like effects in humans following single doses of ethanolic extract or
dried leaf powder of Lemon balm [3–5]; whilst chemically-characterised and combined ethanolic extracts
of sage (S. officinalis L.), rosemary (Rosmarinus officinalis L.; accepted name: Salvia rosmarinus Schleid.)
and Lemon balm improved memory in a randomised, double-blind, placebo-controlled pilot trial [6].
Similarly, single doses of dried leaf [7] and an ethanolic extract [8] of sage; containing a wide
spectrum of phytochemicals, have both been shown to significantly improve mood and cognitive
function. However, the most recent of these studies confirmed that the psychoactive properties
of sage were evident following an essential oil composed exclusively of monoterpenes. This and
other essential oils, as well as a wide range of sage extracts, also exhibited in vitro cholinesterase
inhibiting properties [7,9–16], that were potentially predicated on synergies between the monoterpene
components [12,13].
To date, with the exception of consistent evidence of cognitive/mood effects for sage, Lemon balm
and rosemary, the psychoactive potential of many of the remaining edible aromatic Lamiaceae species
remain under-investigated. One of the most promising groups of plants in this respect is the Mentha
genus and, in particular, Mentha spicata (spearmint) and Mentha × piperita (peppermint); which are
widely used as food components, flavourings and for their medicinal properties. The latter include
uses as antispasmodics [17], anti-emetics [18] and treatments for irritable bowel syndrome and as
topical analgesics [19].
Members of the genus typically express several monoterpenes that provide their “minty” flavour
and odour; most notably menthol, menthone, limonene, piperitone, carvone and their derivatives,
alongside the more typical monoterpenes expressed by related genera [20,21]. These monoterpene
components may exert a number of effects directly relevant to brain function. These include:
cholinesterase inhibition activity by essential oils [20,22,23]; allosteric serotonin 5-hydroxytryptamine-3
(5-HT3) receptor modulation by menthol alone and peppermint oil [24]; negative allosteric modulation
of GABAA receptors by carvone [25]; and positive allosteric modulation of GABAA receptors by
menthol [26–28]. Menthol also exerts several other unique effects which may be tangentially relevant
to central nervous system (CNS) functioning; including the allosteric activation of glycine receptors [26]
and modulation of the function of transient receptor potential cation channel subfamily M member 8
(TRPM8) ”cold menthol” receptors [29] and kappa opioid receptors [30].
In terms of the effects of these CNS interactions, investigations utilizing animal models have
observed increased ambulatory behaviour [31], improved memory [32] and anxiolytic effects which are
potentially driven by modulation of serotonergic or dopaminergic function [33]. Currently, only one
controlled trial has investigated the brain function effects of Mentha species in humans. Here promising
effects were observed on quality of working memory and spatial working memory as well as
improved sleep onset and vigour, alertness and overall mood in a group of 50–70 years olds
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following 90 days supplementation with 600 mg and 900 mg of an aqueous extract of Mentha spicata
(spearmint) that contained the phenolic constituents but not the terpene constituents of the plant
material [34]. The current study extends this research by investigating the cognitive and mood
effects of oral administration of mint essential oil comprised of the volatile terpene phytochemical
constituents of a Mentha plant, in healthy, young humans. A preliminary in vitro analysis assessing
the acetylcholinesterase (AChE) inhibitory properties and GABAA, glutamate N-Methyl-D-aspartic
acid (NMDA) and nicotinic receptor binding properties of a range of organic M. spicata and M. piperita
essential oils was conducted in order to select a treatment liable to exert CNS effects relevant to
cognitive function and mood.
2. Pre-Trial in Vitro Screening of Essential Oils
2.1. Methods
2.1.1. Receptor Binding
Six organic Mentha spicata and M. piperita essential oils were investigated in radioligand
competition binding assays using a range of ligand-gated ion channel radioligands targeting the
GABAA, neuronal nicotinic and NMDA glutamate receptors.
An initial screen was performed at 0.1 mg/mL for each mint essential oil versus [3H]
flunitrazepam, [3H] nicotine and [3H] MK801 (as described in [35]).
A series of dose–response competition binding experiments were then performed with the essential oil
that exhibited the most interesting pattern of receptor binding (test concentrations, 0.0001–1 mg/mL) using
[3H] flunitrazepam, [3H] MK-801 and [3H] nicotine, using well-washed adult rat forebrain membranes [35].
The data were fitted to a non-linear regression dose response curve with variable slope and apparent
pIC50 values determined using GraphPad Prism 4. Apparent pIC50 values Vs [3H] flunitrazepam and
[3H] nicotine were 1.79 ± 0.11 and 1.88 ± 0.24, respectively. No significant effect was seen on [3H]
MK801 binding up to a concentration of 1 mg/mL (n = 3 independent experiments performed in triplicate)
2.1.2. AChE Inhibition
The ability of the essential oils to inhibit acetylcholinesterase (AChE) from Electrophorus electricus
was assessed using the colorimetric method of Ellman [36] as described by Okello et al. [37].
2.1.3. GC-MS Analysis
The GC-MS analyses were performed using an Agilent 7890A GC coupled to an Agilent 5975C MS.
The oils were analysed using the GC-MS method described previously [35]. In summary, chromatography
was performed using a 30 m × 0.25 mm ID × 0.25 µm DB-5 MS column (J & W Scientific Inc., Rancho
Cordova, CA, USA) using a temperature programme of 40–300 ◦C at a rate of 3 ◦C/min. The carrier
gas was helium at a flow rate of 1 mL/min and the injection volume was 1 µL (split 1:10) at 220 ◦C,
via an autosampler. Detection was by MS, fitted with electrospray ionisation source operated at
70 eV, with a source temperature of 180 ◦C; mass spectra were recorded in the range m/z 38–600.
Compounds were identified by comparing retention indices and/or mass spectra with published
data [38,39]. Percentage compositions were calculated by integrating peaks for detected oil constituents in
total ion chromatograms.
2.1.4. Neuronal Calcium Mobilisation
Menthol, the major constituent of M. piperita oil (36% in this test sample) has been previously
shown to stimulate calcium mobilisation in a range of cell types, including neurons [40]. In order to
establish the functional neuronal effects of the chosen essential oil neuronal calcium mobilisation was
quantified in differentiated CAD cells.
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A 2 mM stock of the Calcium Green™-1AM (ThermoFisher Scientific, Cramlington, UK) probe
was prepared in DMSO (Sigma, Poole, UK); this was stored at −20 ◦C for up to 2 months. On the day
of the imaging experiments the probe stock was brought to room temperature and then diluted in
HEPES physiological buffer (150 mM NaCl, 1 mM MgCl2, 10 mM HEPES, 2 mM CaCl2, 5 mM KCl)
to a 1 µM solution. The cells were plated in flat bottom µ-dishes (60 µ-Dish, 35 mm, high glass flat
bottom, Ibidi GmbH). The cells were washed with 1 mL of physiological buffer and incubated for
40 min in 1 mL of the Calcium-Green solution (1 µM). After the incubation period, the cells were
washed again with the HEPES physiological buffer and maintained in HEPES physiological buffer
prior to the imaging experiments. All reagents applied to the clonal cells during the experiments were
dissolved in the HEPES physiological buffer.
The incubation period for each treatment was for periods of 250 cycles (0.63 s each) before the
appliance of the depolarising buffer (50 mM KCl) and then imaged for a further period of 250 cycles.
All the solutions were kept at 37 ◦C to avoid any stress on the cells during the sample preparation and
the imaging experiment. For the imaging, the Zeiss LSM 850 with an Airyscan microscope was used.
The laser used for imaging was set at 514 nm: 1.1% (Ch2GaAsp: 524–620). The spectrum window was
set between 24,620 and a pin hole of 49 µm was used. A size 63 oil lens with an LA of 1.4 was used to
capture each image and the time between each frame (time series) was set at zero. The duration for one
frame was 633.02 ms. To extract the figures and fluorescence intensities, the Zeiss software was used.
The neuroprotective properties of the selected essential oil, assessed in CAD cell cultures subjected
to hydrogen peroxide were also investigated (methods and results in online Supplementary Materials).
2.2. Results
The GABAA, nicotinic and NMDA receptor binding properties, acetylcholinesterase (AChE)
inhibition and major terpene constituents of the 6 organic essential oils included in the initial in vitro
screening are shown in Table 1. The full GC-MS analysis results for the essential oils can be found in
the online supplementary materials (Table S1).
Table 1. Results from the initial screening of essential oils (receptor binding at a concentration of
0.1 mg/mL) and major constituents detected in each Mentha species by GC-MS analysis.
Mentha spicata Mentha × piperita
Essential Oil Number 1 2 3 4 5 6
GABAA receptor
% displacement (3H)
flunitrazepam
35 ± 3 25 ± 2 42 ± 5 42 ± 3 25 ± 2 15 ±2
Nicotinic receptor
% displacement (3H) nicotine 30 ± 3 25 ± 4 21 ± 8 52 ± 5 50 ± 5 49 ± 1
NMDA receptor
% displacement (3H) MK801 0 ± 3 0 ± 2 5 ± 4 0 ± 2 10 ± 3 5 ± 1
AChE Inhibition % 79.45 66.21 70.78 70.09 73.97 73.74
Major constituents detected in each sample by GC-MS
% Limonene 20.8 20.8 18.4 2.3 2.4 2.0
% Carvone 61.9 57.5 58.8 0.1 0.1 0.1
% Menthone 0.4 1.7 0.1 24.9 24.7 24.2
% Menthol 0.5 2.8 0.80 36.7 32.5 34.7
On the basis of high GABAA and nicotinic receptor binding and AChE inhibitory properties,
essential oil 4 (see Table 1) was taken forward into the dose-response experiments and the investigation
of neuronal calcium mobilisation and neuroprotective properties.
In the dose–response competition binding investigation the chosen M. piperita essential oil
inhibited both [3H] nicotine and [3H] flunitrazepam binding in a concentration-dependent manner (and
with similar apparent IC50 values) with no significant effects on [3H] MK801 binding (see Figure 1.).
This was consistent with previous studies focusing on menthol, the major component of M. piperita
oil [41,42].
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Figure 1. Dose-response radioligand binding properties of M. piperita essential oil (sample 4) in adult 
rat forebrain membranes at concentrations between, 0.000 and 1 mg/mL using [3H] flunitrazepam, 
[3H] MK-801 and [3H] nicotine. 
The results of the calcium mobilisation assay are presented in Figure 2. 
 
Figure 2. Effects of M. piperita essential oil on Calcium mobilisation in differentiated CAD cells. M. 
piperita essential oil (0.1 mg/mL) was applied (red arrow) and recorded for 250 cycles. Representative 
of at least 5 cells from 3 separate experiments. (A) Positive modulation on calcium intracellular 
mobilisation. A rapid increase in calcium was observed in the neuronal cell body, which peaked 
approximated cycle 40 post-application (approx. 30 s) and then dropped steadily to a level below the 
original starting concentration at cycle 250. (B) Extension of depolarization—induced calcium 
Figure 1. Dose-response radioligand binding properties of M. piperita essential oil (sample 4) in adult
rat forebrain membranes at concentrations between, 0.000 and 1 mg/mL using [3H] flunitrazepam,
[3H] MK-801 and [3H] nicotine.
The results of the calcium mobilisation assay are presented in Figure 2.
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Figure 2. Effects of M. piperita essential oil on Calcium mobilisation in differentiated CAD
cells. M. piperita essential oil (0.1 mg/mL) was applied (red arrow) and recorded for 250 cycles.
Representative of at least 5 cells from 3 separate experiments. (A) Positive modulation on calcium
intracellular mobilisation. A rapid increase in calcium was observed in the neuronal cell body, which
peaked approximated cycle 40 post-application (approx. 30 s) and then dropped steadily to a level
below the original starting concentration at cycle 250. (B) Extension of depolarization—induced calcium
mobilisation. In the presence of M. piperita essential oil (0.1 mg/mL) for approx. 180 s, a depolarisation
pulse for 250 cycles elicited a rapid calcium increase followed by a delayed decrease compared
to a depolarising pulse alone, which desensitised significantly quicker. (C) Representative images.
Representative images of individual cell body calcium changes in the presence of M. piperita essential
oil (0.1 mg/mL), pre-application, peak of calcium increase and post peak reduction in calcium levels.
Nutrients 2018, 10, 1029 6 of 17
3. Human Intervention Study
3.1. Methods
3.1.1. Participants
24 participants (9 Male/15 Female, Mean age 25.2 years, Range 21–35 years) reported themselves
to be in good health and free from illicit drugs, alcohol, prescription medication (apart from
contraception in the case of women) and herbal extracts/food supplements at each assessment.
Participants confirmed that they would also comply with these exclusion criteria for the duration
of the study and that any changes in medication or health status would be reported to the
researcher when they occurred. Participants who had suffered a head injury, neurological disorder
or neuro-developmental disorder were excluded from participation, as were those who did not have
English as their 1st language (or were not equivalent to a native English speaker; due to the cognitive
tasks utilized here not being validated on non-native English speakers) had any relevant food allergies
or intolerances, digestive problems, smoked tobacco, drank excessive amounts of caffeine (more than
600 mg day as assessed by a caffeine consumption questionnaire), were pregnant, seeking to become
so, or were breast feeding.
The study received ethical approval from the Northumbria University Psychology department
(within the faculty of Health and Life Sciences) ethics committee (code SUB058_Wightman_160216)
and was conducted according to the Declaration of Helsinki (1964). All participants gave their written
informed consent prior to their inclusion in the study.
3.1.2. Treatments
The treatment administered in the study (essential oil number 4) was chosen from six organic
essential oils on the basis of the in vitro pre-screening as described above.
On each study day participants received two 500 µL capsules containing one of the following
treatments:
100 µL Mentha piperita essential oil (in vegetable oil)
50 µL Mentha piperita essential oil (in vegetable oil)
Placebo (vegetable oil)
The individual participants’ treatments were administered double-blind in envelopes with a
peppermint aroma according to the participant’s randomly allocated position on a Latin square
counterbalancing the order of treatments across the cohort. Treatment guess data collected at the
end of the final study visit showed that participants’ ability to identify treatments did not differ from
chance. Capsules were consumed with 200 mL full fat milk (to aid distribution and absorption of lipid
soluble terpenes) under constant supervision.
3.1.3. Cognitive Tasks and Mood Measures
With the exception of the State-Trait Anxiety Inventory, all cognitive tasks and mood measures
were delivered via the Computerised Mental Performance Assessment System (COMPASS; see:
www.cognitivetesting.co.uk), a software platform for the presentation of classic and bespoke computerised
cognitive tasks, with fully randomised parallel versions of each task delivered at each assessment for each
individual. Tasks were presented on a laptop PC with responses made either via a four button response
box, with mouse and cursor, or by the keyboard’s linear number pad. The tasks and other components
of each assessment are described below in order of completion. The timelines of each assessment are
shown in Figure 2. Similar selections of tasks have previously been shown to be sensitive to a number of
nutritional interventions [11,43,44].
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3.1.4. State-Trait Anxiety Inventory (STAI) [45]
During the training/screening session, participants completed the entire pen and paper STAI to
indicate general levels of state and trait anxiety. During the testing session participants completed the
state subscale only. The STAI state subscale is a widely used instrument for measuring fluctuating
levels of anxiety. The subscale contains 20 statements (e.g., “I am calm”) each with a 4-point Likert
scale. Participants rate how much they feel like each statement at the time of making the response.
Scores on the STAI range from 20 to 80, with higher scores representing higher levels of anxiety.
3.1.5. Bond-Lader Mood Scales [46]
These mood scales have been utilised in numerous pharmacological, psychopharmacological
and medical trials. These scales comprise a total of sixteen 100 mm lines anchored at either end
by antonyms (e.g., “alert-drowsy,” “calm-excited”). Participants indicate their current subjective
position between the antonyms on the line. Outcomes comprise three factor analysis derived scores:
“Alertness”, “Calmness” and “Contentment”.
3.1.6. Picture Presentation
Fifteen black-and-white photographic images of objects and outdoor and indoor scenes were
presented sequentially on screen for the participant to remember at the rate of 1 every 3 s, with a
stimulus duration of one second. The same set of fifteen pictures was presented to each participant in
a random order.
3.1.7. Face Presentation
A set of twelve passport-style photographic images of people were presented sequentially in a
random order to participants. A first and last name was assigned to each photograph and presented
on the screen underneath the person’s face. Stimulus duration was one second, with a 3-second
inter-stimulus duration.
3.1.8. Word Presentation
A unique set of fifteen words was presented. Words were selected at random from a large bank of
words derived from the MRC Psycholinguistic Database [47] and matched for word length, frequency,
familiarity and concreteness. Stimulus duration was one second, as was the inter-stimulus duration.
3.1.9. Immediate Word Recall
The participant was allowed 60 s to write down as many of the words as possible. The task was
scored for number correct and errors.
3.1.10. Numeric Working Memory
Five random digits from 1–9 were presented sequentially for the participant to hold in memory.
This was followed by a series of 30 probe digits (15 targets and 15 distractors). For each, the participant
indicated whether or not it had been in the original series by a simple key press. The task consisted of
3 separate trials. Accuracy (% correct) and mean reaction time (ms) were recorded.
3.1.11. Corsi Blocks Task
In this task, nine identical blue squares appeared on screen in non-overlapping random positions.
A set number of blocks changed colour from blue to red in a randomly generated sequence. The cursor
was locked in position until the entire sequence had been presented; at which point the participants
were instructed to repeat the sequence by clicking on the blocks using the mouse and cursor. The task
was repeated five times at each level of difficulty. The sequence span increased from 4 upwards, until
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the participant could no longer correctly recall the sequence, resulting in a span measure of nonverbal
working memory, calculated by averaging the level of the last five correctly completed trials.
3.1.12. Choice Reaction Time (CRT)
The CRT task requires participants to indicate, by pressing the “left” or “right” response box
button, the direction of the arrow presented on the computer screen. Fifty stimuli (arrows) are
presented, with varying delays, taking ~2 min to complete, depending on participant reaction time.
The task is scored for percentage correct responses and reaction time (ms).
3.1.13. RVIP (Completed Separately and as Part of the CDB)
The RVIP task requires the participant to monitor a continuous series of single digits for targets of
three consecutive odd or even numbers. The white digits are presented on the black computer screen at
the rate of 100 per minute; with eight correct target strings in each minute presented in pseudo-random
order. The participant responds to the detection of a target string by pressing the appropriate response
button as quickly as possible. In terms of task outcomes, RVIP is scored for number of target strings
correctly detected and the average reaction time (ms) for correct detections.
3.1.14. Cognitive Demand Battery (CDB)
Multiple completions of this 9 min battery of tasks reliably increase self-ratings of mental fatigue
and is sensitive to many natural interventions [48–51]. Two minutes each of Serial 3 and 7 subtractions is
first completed and followed immediately by 5 min of Rapid Visual Information Processing (RVIP—as
described above). Mental fatigue is self-rated after each completion of the three tasks.
Serial 3 and 7 subtractions: At the start of the 2 min task a standard instruction screen informs the
participant to count backwards in 3 s or 7 s as quickly and accurately as possible, using the keyboards
linear number keys to enter each response. Participants are instructed verbally at the outset that if
they make a mistake they should carry on subtracting from the new incorrect number with subsequent
responses scored as correct in relation to the new number. To begin, a random starting number
between 800 and 999 is presented on the computer screen, which is cleared by the entry of the first
response. Each three-digit response was represented on screen by three asterisks which disappeared
after enter was pressed to signal completion of the response. Outcomes are the total number of correct
subtractions and the number of incorrect responses.
3.1.15. Peg and Ball
Two configurations of wooden peg (×3) and ball (×3; blue, green and red) diagrams are displayed,
on screen, with the top diagram denoting the “goal” configuration of balls on pegs. Participants must
rearrange the balls on the “starting” configuration below this to match the “goal.” They must do this in the
least number of moves possible. The task is scored for average thinking time (ms), average completion
time (ms) and errors (total number of moves in excess of minimum required to complete all trials).
3.1.16. Delayed Word Recall
Participants had 60 s to note down as many of the words from the list presented at the beginning
of the task battery as they can remember. The task was scored for number correct and errors.
3.1.17. Delayed Face to Name Recall
The target faces presented at the beginning of the battery were displayed on the screen one at a
time. Below each face is a list of 4 forenames and a list of 4 surnames. Participants use the mouse to
select the forename and surname that they think were associated with each face at the beginning of
the session. The task outcomes include percentage accuracy for overall correct forenames and correct
surnames and reaction time (ms).
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3.1.18. Delayed Picture and Word Recognition
Word and picture recognition were completed separately. In each task participants differentiate,
by pressing “yes” or “no” on the response box, between the 15 target words and pictures presented at
the beginning of the test battery and 15 randomly interspersed decoy words and pictures. The tasks
take ~2 min to complete and are scored for percentage of correctly recognised words/pictures and
reaction time (ms).
See Figure 3 for the running order of the individual cognitive assessments within the 75 min
task battery.
Nutrients 2018, 10, 1029 9 of 17 
select the forename and surname that they think were associated with each face at the beginning of 
the session. The task outcomes include percentage accuracy for overall correct forenames and correct 
surnames and reaction time (ms). 
3.1.18. Delayed Picture and Word Recognition 
Word and picture recognition were completed separately. In each task participants differentiate, 
by pressing “yes” or “no” on the response box, between the 15 target words and pictures presented 
at the beginning of the test battery and 15 randomly interspersed ecoy words and pictures. The tasks 
take ~2 min to c mplete and are scored for percentage of correctly recognised words/pictures and 
reaction time (ms). 
See Figure 3 for the running order of the individual cognitive assessments within the 75 min task 
battery. 
 
Figure 3. Running order of tasks administered during each assessment. 
Word, Picture, 
Face/Name 
presentation
Immediate Word Recall
Stimuli
Presentation
Working Memory 
Attention
Episodic Memory
Minutes
Executive
Function
Choice Reaction Time
Numeric Working Memory
RVIP
Bond Lader Mood Scales
Delayed Name/Face Recall
Delayed Word Recall
Delayed Pic’ Recognition
Delayed Word Recognition
Spatial
Working Memory
Episodic Memory
0
5
10
15
20
65
Corsi Blocks
Peg and Ball Task
Mood
70
Cognitive Demand 
Battery
40 Minutes
4 repetitions of 
Serial 3s, Serial 
7s, RVIP, VAS
Cognitive Demand
(working memory
executive function
attention)
Figure 3. Running order of tasks administered during each assessment.
Nutrients 2018, 10, 1029 10 of 17
3.2. Procedure
Participants were required to attend the laboratory on 4 separate occasions, the last three of which
were separated by a 7 day wash-out period. The first of the visits was a training/screening session
where participants gave consent and were briefed and screened against the exclusion criteria before
completing several repetitions of the cognitive tasks described above to ensure they were familiar and
capable of completing the tasks during the ensuing testing sessions.
The further 3 visits were testing sessions in which participants arrived at the testing facility at
8:00 a.m., having consumed no food for 12 h, caffeine for 18 h, alcohol for 24 h and mint-containing
products for 48 h. Upon arrival, participants were screened to ensure that they still met the inclusion
criteria and their light breakfast (to have been consumed before 7:30 a.m.) was noted. They then
underwent a baseline cognitive and mood measurement at 8:15 a.m. Here the “state” subscale
of the STAI was completed first followed by the 75 min cognitive testing battery (see Figure 3).
Treatment capsules were then immediately consumed in the presence of the researcher. The cognitive
assessment was then repeated commencing at 1 h, 3 h and 6 h post-dose, with a standard lunch
provided after the 3 h post-dose assessment. During breaks between testing participants waited in a
comfortable waiting room. The timelines of the testing day are represented in Figure 4.
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3.3. Statistics
Statistical analyses were carried out using IBM SPSS statistics 22. Prior to analysis, task/mood
data from the three post-dose assessments (1 h, 3 h, 6 h) was converted to “% change from pre-dose
baseline” (Serial 3 s/7 s errors and Word Recall scores were analysed as simple numeric “change from
baseline” due to the potential to score zero at baseline). In order to examine the time course of any
effects of the essential oils across the testing day, the primary analysis of all task/mood data was
undertaken with a priori planned comparisons, comparing data (averaged across 4 repetitions for
CDB tasks) from the placebo condition to that from each of the two active treatments at each post-dose
time point using t tests calculated using MSError from an initial omnibus within-subjects ANOVA.
To reduce the possibility of Type II errors, planned comparisons are only reported for those measures
that evinced a significant treatment related effect on the initial ANOVA or related multivariate test.
3.4. Results
Prior to the treatment code break and the analysis of cognitive task performance two participants
were removed from the dataset due to inconsistent performance.
Nutrients 2018, 10, 1029 11 of 17
3.4.1. Cognitive Demand Battery
Mental Fatigue
Reference to the planned comparisons of % change from baseline data showed that subjective
ratings of Mental Fatigue were significantly reduced in comparison to placebo following the higher
dose of 100 µL of essential oil during the 3 h post-dose assessment (T (264) = 2.92, p < 0.01).
(Multivariate treatment x assessment interaction (F (4, 19) = 3.56, p < 0.05)).
Rapid Visual Information Processing Task
Reference to the planned comparisons of % change from baseline data showed that, in comparison
to placebo, accuracy on the RVIP task was significantly enhanced following the higher dose (100 µL)
of essential oil during the 1 h (T (252) = 2.88, p < 0.01) and 3 h (T (252) = 2.04, p < 0.05) post-dose
assessments. (Multivariate main effect of treatment (F (2, 20) = 3.84, p < 0.05)).
Serial 3 s Subtractions
Reference to the planned comparisons of % change from baseline data showed that, in comparison
to placebo, participants completed more correct Serial 3 s following the higher dose (100 µL) of essential
oil during the 3 h (T (252) = 2.92, p < 0.01) post-dose assessment. (ANOVA treatment x assessment
interaction (F (4, 252) = 2.64, p < 0.05)).
Serial 7 s Subtractions
Whilst there was a treatment x assessment interaction effect with regards Serial 7 s errors (ANOVA
(F (4, 252) = 3.3, p < 0.05) this only resulted in a trend towards reduced errors following the higher
dose, relative to placebo, during the 3 h assessment (T (252) = 1.9, p < 0.1).
The measures evincing significant treatment related improvements are represented graphically in
Figure 5. Data for the Cognitive Demand Battery tasks are presented in Table 2.
Table 2. Cognitive Demand Battery pre-dose baseline (raw) data and “% change from baseline” data
for the 1 h, 3 h and 6 h assessments. Serial 3 s/7 s errors post-dose scores are “change from baseline”
(due to potential zero scores). All data shown are average scores across the 4 repetitions of each task
during each assessment. Scores are mean (+ SEM).
Assessment
TASK Treatment Baseline 1 h 3 h 6 h
Mental Fatigue
(% VAS)
100 µL 61.81 4.08 11.46 5.32 10.16 6.40 21.42 7.92
50 µL 58.10 3.92 12.43 7.26 17.70 7.55 26.28 7.73
placebo 57.53 3.86 9.13 5.54 23.16 6.21 24.63 5.78
RVIP (% correct)
100 µL 51.05 4.55 2.78 4.01 −8.29 2.51 −9.77 2.91
50 µL 57.19 4.01 −4.47 3.27 −13.07 3.37 −13.4 3.66
placebo 54.43 3.72 −11.96 4.30 −15.73 3.23 −18.2 3.32
RVIP (speed—ms)
100 µL 477.11 9.68 −2.21 0.97 −2.97 1.13 −2.40 1.43
50 µL 474.48 11.47 −0.13 0.66 −0.45 0.59 −1.04 0.99
placebo 484.23 11.67 −2.88 0.80 −1.95 0.95 −2.53 1.07
Serial 7 s
(number correct)
100 µL 29.17 2.24 6.22 2.18 9.90 4.29 8.34 3.52
50 µL 29.11 2.55 4.75 3.00 10.11 3.15 8.21 4.18
placebo 28.86 2.58 8.89 4.87 9.11 3.64 10.08 4.65
Serial 7 s
(errors)
100 µL 2.24 0.33 0.05 0.26 0.51 0.32 −0.15 0.25
50 µL 1.91 0.32 0.00 0.32 0.39 0.19 −0.10 0.38
placebo 2.08 0.36 −0.28 0.27 0.20 0.33 −0.40 0.27
Serial 3 s
(number correct)
100 µL 46.83 3.48 5.14 2.28 11.59 3.83 7.50 3.09
50 µL 46.93 3.77 4.17 2.44 5.64 4.14 2.59 3.55
placebo 46.61 3.50 3.96 2.26 1.83 2.27 5.14 2.61
Serial 3 s
(errors)
100 µL 2.19 0.36 0.47 0.33 −0.33 0.41 0.13 0.22
50 µL 2.44 0.43 −0.56 0.28 0.01 0.49 0.60 0.29
placebo 1.60 0.26 −0.27 0.30 −0.48 0.37 −0.34 0.19
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3.4.2. Individual Cognitive Tasks
Word Recall errors was the only individual cognitive task outcome to evince a significant ANOVA
result (F (4, 88) = 5.4, p < 0.001). However, reference to the planned comparisons showed that there
were no significant differences between placebo and the low and high doses of essential oil. The data
from the individual cognitive tasks are presented in the on-line Supplementary Table S2.
3.4.3. Mood
There were no significant differences on the mood measures (State-Trait Anxiety Inventory—state
subscale and Bond-Lader “alert,” “content” and “calm”).
The data from the mood measures are presented in the on-line Supplementary Table S3.
4. Discussion
In this study, the peppermint (Mentha × piperita) essential oil selected for the human behavioural
study exhibited in vitro concentration-dependent GABAA and nicotinic receptor binding properties
and inhibited acetylcholinesterase. When administered to human adults the higher dose of essential oil
(100 µL) resulted in improvements in performance across two of the three Cognitive Demand Battery
(CDB) tasks, with a trend towards improved performance on the third task. In terms of individual
tasks, the accuracy of performing the RVIP task was significantly improved during the 1 h and 3 h
post-dose assessments, whilst the number of correct Serial 3s subtractions was significantly increased
at 3 h post-dose. This latter finding also coincided with a trend towards improved accuracy on the
Serial 7s task and a significant attenuation of the subjective mental fatigue experienced by the placebo
group at the same time point. Performance on the individual cognitive tasks (i.e., those only repeated
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once per assessment) and measurements of anxiety (STAI-state) and psychological state (Bond-Lader)
were not modulated by the treatment.
Naturally, this pattern of effects raises the question as to why performance of the CDB was
preferentially affected. The underlying rationale for this approach to testing, whereby participants
engage in an extended period of demanding task performance, is that the increase in neuronal or
psychological demands provides a more sensitive background against which to measure treatment
related effects. This may be due either to the rate-limiting depletion of physiological brain resources
during extended task performance, or alternatively, the increased level of engagement required by
the participants. Certainly, this approach has proved sensitive to the cognitive/mental fatigue effects
of a wide range of nutritional interventions [11,50,52]. An alternative explanation might be that the
CDB involves four repetitions of each task (i.e., 4 times as much data), thereby increasing the statistical
power of these measures to detect treatment related effects.
In terms of in vitro properties, all of the spearmint/peppermint oils were confirmed to have the
expected terpene constituents (as defined in the British Pharmacopoeia (www.pharmacopoeia.co.uk),
with the spearmints typified by high levels of limonene and carvone, while the peppermints contained
high levels of menthol and menthone (see Table 1). The essential oil chosen for the behavioural study
had the highest level of menthol (36.7%) and it exhibited both concentration dependent GABAA and
nicotinic receptor binding properties, alongside significant inhibition of acetylcholinesterase (thereby
potentially increasing the synaptic availability of acetylcholine). The GABAergic and cholinesterase
inhibitory effects are broadly in line with previous investigations of Mentha × piperita [42] and other
members of the Mentha genus [53]. With regards the nicotinic receptor binding, whilst there is a dearth
of research assessing the effects of M. piperita extracts per se, menthol has been shown to modulate
nicotinic receptor populations and sensitivity and inhibit nicotinic receptor mediated activity [41,54].
Similar observations have been noted with the essential oil from another member of the Lamiaceae,
Melissa officinalis (Chazot, unpublished). In the current study, the post-hoc investigation of calcium
mobilisation in a CAD cell neuronal model showed an increase in activity following application of
the essential oil. It seems likely that the effects here were predicated on cholinergic upregulation,
rather than any aspect of GABAergic modulation. Indeed, the behavioural consequences of increased
GABAergic activity (which is inhibitory) would be expected to include modulation of mood and
anxiolytic properties and potential selective impairments to cognitive function. Here, the improved
performance on the Cognitive Demand Battery; which requires considerable attentional resources,
would fit well with the theory of upregulated cholinergic activity. The disjunction between observations
of in vitro downregulation of nicotinic receptor mediated activity by menthol [41,54] and potential
cholinergic improvements in cognitive function and mental fatigue following the essential oil could
be explained by several factors. First, the effects here could have been predicated on synergistic
effects between component terpenes; with menthol contributing to, rather than driving the effects
of the essential oil. Such synergistic effects have been seen previously with regards, for instance,
AChE inhibition [12,13]. Second and similarly, the effects may have represented the balance between
menthol’s receptor mediated downregulation of nicotinic activity and the essential oil’s AChE
inhibition related upregulation of acetylcholine levels. Third, in vitro effects are typically measured
within a short period of application and the behavioural effects here may be predicated on later
effects that are different in nature, including a potential physiological “rebound” triggered by the
immediate effects on cellular function. Fourth, the cholinergic effects of menthol may differ depending
on the nature of the neural tissue (e.g., downregulation has typically been shown in sensory neurons).
Peppermint (Mentha × piperita) essential oil also elicited an increase in [Ca2+] and an extension of
the depolarisation response as previously reported for menthol; a major constituent of the oil [55].
The neuroprotective properties in the face of oxidative stress displayed by M. piperita in CAD cells
(online Supplementary Appecndix I) is consistent with a previous study with a related cell line [42].
These pharmacological functional effects may also contribute, in part, to the positive cognitive effects
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of M. piperita. Of course, the net effects of the essential oil may be a result of a combination of these
factors or, indeed, a host of other mechanisms of action that were not addressed in this study.
Interestingly, a previous study that assessed the cognitive effects of 50 µL of essential oil from
sage (Salvia lavandulaefolia Vahl.; synonym for Salvia officinalis subsp. lavandulifolia (Vahl) Gams), which
is in the same sub-family as M. piperita and synthesises many similar monoterpenes, demonstrated
decreased mental fatigue and improved Serial 3 s subtractions using the same Cognitive Demand
Battery [11]. As here, the effects were greater at a later time point (4 h post-dose) than at 1 h post-dose.
In the previous sage study the cognitive effects also extended to the other individual cognitive tasks
and included improved alertness and memory. The lower dose for the current study was selected
on the basis of this previous study and given that the lower dose (50 µL) administered here was less
effective, it seems likely that 100 µL of M. piperita essential oil may represent the lower reaches of
this oil’s dose-response profile. If this is the case, higher doses of this oil may well result in a more
comprehensive pattern of cognitive/mood effects. This possibility, alongside research disentangling the
behavioural effects of the major components of these essential oils, deserves further research attention.
In conclusion, a peppermint (M. piperita) essential oil with high levels of menthol and menthone
and characteristic in vitro AChE inhibitory, calcium regulatory, GABAA receptor and nicotinic receptor
binding properties, beneficially modulated performance of demanding cognitive tasks and attenuated
the increase in mental fatigue associated with extended cognitive testing. These effects were only
evident for the higher (100 µL) of the two doses investigated; raising the possibility that doses of this
essential oil in excess of 100 µL would exert greater effects in terms of cognitive/mood enhancement.
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6643/10/8/1029/s1,
Table S1: Percentage composition of compounds detected in the Mentha spicata and Mentha × piperita essential
oils, obtained from the GC-MS total ion chromatograms, Table S2: Individual cognitive task performance: pre-dose
baseline (raw) data and ‘% change from baseline’ data for the 1 h, 3 h and 6 h assessments. Immediate and Delayed
Word Recall correct and error post-dose scores are ‘change from baseline’ (due to potential zero scores). Scores are
mean (+ SEM), Table S3: Mood data: pre-dose baseline (raw) data and ‘% change from baseline’ data for the 1 h,
3 h and 6 h assessments. Appendix I: in vitro neuroprotective properties–method and results.
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